伊曲康唑治疗恶性肿瘤患者真菌感染疗效评价

Clinical efficacy of itraconazole in treatment of malignant tumor patients with complicated fungal infections

目的探讨伊曲康唑治疗恶性肿瘤患者真菌感染的临床疗效与安全性,为临床诊治提供参考。方法选取2012年1月-2014年12月在医院接受治疗的64例恶性肿瘤真菌感染患者作为研究对象,将其随机分为研究组与对照组,各32例,研究组采用伊曲康唑进行治疗,对照组采用氟康唑进行治疗,对比两组患者的临床疗效及不良反应的发生率。结果患者抗真菌治疗的有效率研究组为81.25%、对照组为56.25%,研究组患者抗真菌治疗效果明显高于对照组,两组间比较差异有统计学意义(P<0.05);研究组患者不良反应发生率为18.75%、对照组为12.5%,两组患者不良反应发生率比较差异无统计学意义。结论对恶性肿瘤患者侵袭性真菌感染采用伊曲康唑抗真菌治疗,临床效果明显,且安全性较高,值得在临床推广。

OBJECTIVE To observe the clinical efficacy and safety of itraconazole in treatment of the malignant tumor patients with complicated fungal infections so as to provide guidance for clinical treatment .METHODS A to‐tal of 64 malignant tumor patients with complicated fungal infections who were treated in the hospital from Jan 2012 to Dec 2014 were recruited as the study objects and randomly divided into the study group and the control group ,with 32 cases in each .The study group was treated with itraconazole ,while the control group was given fluconazole;the clinical efficacies and incidence of adverse reactions were observed and compared between the two groups of patients .RESULTS The effective rate of antifungal treatment of the study group was 81 .25% ,signifi‐cantly higher than 56 .25% of the control group（P〈0 .05）;the incidence of adverse reactions was 18 .75% in the study group ,12 .5% in the control group ,and there was no significant difference in the incidence of adverse reac‐tions between the two groups .CONCLUSION Itraconazole can achieve significant clinical effect on antifungal treat‐ment of the malignant tumor patients with complicated invasive fungal infections ,with the safety higher ,and it is worthy to be promoted in the hospital .